eTheRNA   Report issue

For profit Phase 1 Phase 2
Founded: Jette Belgium (2013)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2017
NCT02888756
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

eTheRNA immunotherapies

Active Ingredients

Drugs in Phase 2 Trials (5)

alprostadil (prostin) (2 trials)

ihivarna (1 trial)

papaverine (2 trials)

phentolamine mesylate (regitine) (2 trials)

trimix (2 trials)

Drugs in Phase 1 Trials (1)

eci-006 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

HIV Infections (Phase 2)

Infections (Phase 2)

Melanoma (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 6